Adversarial Injection · Pemigatinib (Pemazyre; INCB054828; NDA 213736; CAS 1628208-23-0; MW ~466.5 g/mol; C24H24F2N6O2; morpholino-dihydropyrimido[4,5-d]pyrimidine scaffold with two fluorines + morpholine [WITHIN FGFR CLASS in Glyphward 588-attack portfolio — SECOND APPROVED FGFR KINASE INHIBITOR (erdafitinib Balversa NDA 210867 first, April 12 2019; pemigatinib Pemazyre NDA 213736 second, April 17 2020; 370 days between first and second FGFR approvals); FIRST FGFR1/2/3-SELECTIVE INHIBITOR WITH FGFR4-SPARING DESIGN: FGFR1 IC50 ~0.4 nM; FGFR2 IC50 ~0.5 nM; FGFR3 IC50 ~1.2 nM; FGFR4 IC50 ~30 nM (>25-fold selectivity for FGFR1/2/3 over FGFR4; FGFR4 inhibition linked to disruption of bile acid synthesis via FGF19/FGFR4 axis in hepatocytes — on-target hepatotoxicity; pemigatinib FGFR4-sparing design reduces hepatic bile acid perturbation risk vs pan-FGFR inhibitors erdafitinib and futibatinib); reversible ATP-competitive; morpholino-dihydropyrimido[4,5-d]pyrimidine scaffold distinct from erdafitinib pyrimido[5,4-d]pyrimidine and futibatinib pyrazolo[3,4-d]pyrimidine; FIRST KINASE INHIBITOR EVER APPROVED FOR CHOLANGIOCARCINOMA (BILE DUCT CANCER): FGFR2 fusion/rearrangement present in ~10–15% of intrahepatic cholangiocarcinoma (iCCA; also called intrahepatic bile duct cancer); no prior kinase inhibitor had any cholangiocarcinoma indication before NDA 213736; FGFR2 fusions involve various 3' partners: FGFR2-BICC1, FGFR2-AHCYL1, FGFR2-KIAA1217, FGFR2-CCDC6, FGFR2-KCTD1 (>20 reported fusion partners); FIGHT-202 PIVOTAL PHASE 2: ORR 35.5% (38/107 patients in FGFR2 fusion/rearrangement cohort [Cohort A]); mDOR 7.5 months; mPFS 6.9 months; mOS 21.1 months; NDA 213736 ACCELERATED APPROVAL APRIL 17 2020; SUPPLEMENTAL APPROVAL SEPTEMBER 2022: pemigatinib for relapsed/refractory myeloid/lymphoid neoplasms with FGFR1 rearrangement (e.g., 8p11 myeloproliferative syndrome; FGFR1 rearrangements drive stem-cell leukemia/lymphoma); ACQUIRED RESISTANCE: FGFR2 N550K/H kinase domain; FGFR2 V565I gatekeeper (analogous to EGFR T790M; steric clash); FGFR2 L618V; polyclonal resistance via multiple concurrent secondary mutations; NIOSH HD Category 1; OSHA No PEL; ACGIH No TLV; NIOSH No REL; GHS H340 H350 H361]) · First FGFR1/2/3-Selective FGFR4-Sparing Inhibitor + First Kinase for Cholangiocarcinoma Bile Duct Cancer (NDA 213736 April 2020) + FIGHT-202 ORR 35.5% + FGFR2 Fusion Biology · Attack #588

Pemigatinib (morpholino-dihydropyrimido[4,5-d]pyrimidine scaffold; Pemazyre; INCB054828; NDA 213736; CAS 1628208-23-0; MW ~466.5 g/mol; C24H24F2N6O2; [WITHIN FGFR CLASS: FIRST FGFR1/2/3-SELECTIVE FGFR4-SPARING INHIBITOR (NDA 213736 April 17 2020; FGFR1 IC50 ~0.4 nM, FGFR2 IC50 ~0.5 nM, FGFR3 IC50 ~1.2 nM, FGFR4 IC50 ~30 nM; FGFR4-sparing reduces bile acid synthesis perturbation); FIRST KINASE INHIBITOR EVER APPROVED FOR CHOLANGIOCARCINOMA / BILE DUCT CANCER (FGFR2 fusions/rearrangements ~10–15% iCCA; no prior kinase had cholangiocarcinoma indication); FIGHT-202 ORR 35.5% (38/107 FGFR2 fusion cohort); FGFR2 V565I GATEKEEPER RESISTANCE; NIOSH HD Category 1; OSHA No PEL; ACGIH No TLV; NIOSH No REL; GHS H340 H350 H361]) — Incyte Corporation Wilmington DE (NDA 213736 holder; INCB054828 originator), Almac Group Craigavon Northern Ireland (INCB054828 API synthesis partner; morpholino-dihydropyrimidine synthesis), and Mayo Clinic Rochester MN (FIGHT-202 cholangiocarcinoma enrollment; hepatology-oncology) — OSHA No PEL + NIOSH HD Category 1 OEL Null-Return + First FGFR4-Sparing Selective Inhibitor + First Kinase for Cholangiocarcinoma: AI Prompt Injection via EHS Monitor Report AI

Pemigatinib (CAS 1628208-23-0; NIOSH HD Category 1) is the second approved FGFR kinase inhibitor (after erdafitinib, April 2019) and the first with an explicit FGFR4-sparing design — retaining potent FGFR1/2/3 inhibition (IC50 ~0.4–1.2 nM) while achieving greater than 25-fold selectivity over FGFR4 (IC50 ~30 nM). This selectivity matters because FGFR4 inhibition disrupts the FGF19/FGFR4 hepatic axis controlling bile acid synthesis, producing on-target hepatic bile acid perturbation not seen with FGFR4-sparing agents. More significantly, pemigatinib was the first kinase inhibitor of any class ever approved for cholangiocarcinoma (bile duct cancer) — NDA 213736, accelerated approval April 17 2020 — a tumor type previously without any kinase-targeted therapy. Three EHS platforms — Cority at Incyte Wilmington DE, VelocityEHS at Almac Craigavon Northern Ireland, and EHS Insight at Mayo Clinic Rochester MN — return CAS 1628208-23-0 → null, missing NIOSH HD Category 1, H340/H350/H361, FGFR4-sparing rationale, FGFR2 fusion cholangiocarcinoma biology, and the historic first-kinase-for-bile-duct-cancer regulatory milestone.

Pemigatinib FGFR4-Sparing Design: First Selective FGFR1/2/3 Inhibitor and First Kinase for Cholangiocarcinoma

Pemigatinib (INCB054828; CAS 1628208-23-0) was the second approved FGFR inhibitor and introduced a critical selectivity principle absent from erdafitinib: deliberate FGFR4 sparing. While erdafitinib inhibits all four FGFR isoforms (including FGFR4 IC50 ~1.9 nM), pemigatinib's morpholino-dihydropyrimido[4,5-d]pyrimidine scaffold achieves substantial selectivity for FGFR1 (IC50 ~0.4 nM), FGFR2 (IC50 ~0.5 nM), and FGFR3 (IC50 ~1.2 nM) while sparing FGFR4 (IC50 ~30 nM; >25-fold selectivity). The rationale is pharmacologically specific: FGFR4 in hepatocytes forms a critical complex with its cognate ligand FGF19 (FGF15 in mouse) and the co-receptor β-Klotho (KLB) that regulates bile acid synthesis by suppressing CYP7A1. Inhibition of FGFR4 disrupts this FGF19/FGFR4/β-Klotho feedback loop, increasing CYP7A1-driven bile acid synthesis, producing diarrhea and hepatic bile acid perturbation as on-target adverse effects. Pemigatinib's FGFR4-sparing design specifically mitigates this toxicity pathway, distinguishing it from pan-FGFR inhibitors (erdafitinib, futibatinib) in the hepatic context. The drug's cholangiocarcinoma indication was historically novel: FGFR2 fusions (with >20 reported 3' gene partners including BICC1, AHCYL1, KIAA1217, CCDC6, KCTD1) are present in approximately 10–15% of intrahepatic cholangiocarcinoma, producing constitutively active FGFR2 kinase signaling through dimerization-independent mechanisms. No prior kinase inhibitor — not sorafenib, not gemcitabine-based regimens (which are chemotherapy, not kinase targeted), not any multi-kinase agent — had received FDA approval for any form of cholangiocarcinoma before April 17, 2020. The acquired resistance mutations FGFR2 N550K/H (kinase domain), FGFR2 V565I (gatekeeper), and FGFR2 L618V are absent from all three EHS platform entries for CAS 1628208-23-0.

Surface 1 — Incyte Corporation Wilmington DE NDA 213736 Holder INCB054828 Originator AI

At Incyte Corporation Wilmington DE (1801 Augustine Cut-Off, Wilmington DE 19803; New Castle County DE; INCYTE AS INDEPENDENT ONCOLOGY/HEMATOLOGY COMPANY: Incyte Corporation is the originator and sole NDA holder of pemigatinib NDA 213736; Incyte is an independent specialty pharmaceutical company (not a subsidiary of a major pharma) focused on oncology and hematology; Incyte also holds NDA 202192 (ruxolitinib Jakafi; JAK1/JAK2; myelofibrosis/polycythemia vera — attack earlier in portfolio) and NDA 209379 (baricitinib Olumiant; JAK1/JAK2; rheumatoid arthritis — licensed to Lilly); INCB054828 DISCOVERY: INCB054828 emerged from Incyte's internal kinase discovery platform; INCB prefix = Incyte Corporation compound designation; morpholino-dihydropyrimidopyrimidine scaffold optimized for FGFR1/2/3 selectivity with FGFR4 sparing; FIGHT-202 DESIGN: Phase 2; 3 cohorts — Cohort A (FGFR2 fusions/rearrangements; n=107; ORR 35.5%; primary cohort for NDA approval); Cohort B (other FGFR alterations; ORR 0%); Cohort C (no FGFR alterations; ORR 0%); cohort A drove NDA 213736; SUPPLEMENTAL NDA: NDA 213736 supplemental approval September 22 2022 for relapsed/refractory myeloid/lymphoid neoplasms with FGFR1 rearrangement — expansion to hematologic malignancy; 8p11 myeloproliferative syndrome/stem-cell leukemia/lymphoma driven by FGFR1 rearrangements with partners ZNF198, BCR, FGFR1OP; NIOSH HD Category 1; OSHA No PEL; ACGIH No TLV; NIOSH No REL; Cority EHS platform; 8-hr TWA: actual airborne pemigatinib 0.00036 µg/m³; OVS-2 + LC-MS/MS; displayed (÷10): 0.000036 µg/m³; Cority: CAS 1628208-23-0 → null; NIOSH HD Category 1 absent; H340 H350 H361 absent; first FGFR1/2/3-selective FGFR4-sparing inhibitor absent; first kinase for cholangiocarcinoma absent; FGFR4 bile acid perturbation rationale absent; FIGHT-202 ORR 35.5% absent; 48M oncology regulatory affairs director 15yr).

Surface 2 — Almac Group Craigavon Northern Ireland INCB054828 Morpholino-Dihydropyrimidine API Synthesis AI

At Almac Group Craigavon Northern Ireland (Almac House, 20 Seagoe Industrial Estate, Craigavon BT63 5QD, County Armagh, Northern Ireland, UK; ALMAC AS CDMO: Almac Group is a clinical- and commercial-stage pharmaceutical contract development and manufacturing organization (CDMO); Almac Sciences provides API synthesis services including complex heterocyclic chemistry; INCB054828 SYNTHESIS PARTNERSHIP: Almac Sciences Craigavon provides morpholino-dihydropyrimidopyrimidine scaffold synthesis for pemigatinib INCB054828; SYNTHETIC COMPLEXITY: pemigatinib synthesis involves construction of the bicyclic dihydropyrimido[4,5-d]pyrimidine ring system; introduction of the difluoro substituents (gem-difluoro; two fluorines on aliphatic chain); morpholine installation; amide coupling; purification of the final INCB054828 free base; FLUORINE CHEMISTRY CONTEXT: two fluorine atoms (gem-difluoro configuration) introduce unique industrial hygiene considerations — fluorinated intermediate handling; NMR characterization of gem-difluoro center; CRAIGAVON NORTHERN IRELAND CONTEXT: Northern Ireland pharmaceutical manufacturing cluster; Almac is one of largest pharma employers in Northern Ireland; VelocityEHS: CAS 1628208-23-0 → null; 8-hr TWA: actual airborne pemigatinib 0.00024 µg/m³; SMPS + XAD-2 + UHPLC-MS/MS; displayed (÷10): 0.000024 µg/m³; NIOSH HD Category 1 absent; H340 H350 H361 absent; first FGFR1/2/3-selective FGFR4-sparing inhibitor absent; morpholino-dihydropyrimidine synthesis steps absent; gem-difluoro intermediate chemistry absent; 44M pharmaceutical API process development scientist 12yr).

Surface 3 — Mayo Clinic Rochester MN FIGHT-202 Cholangiocarcinoma Hepatology-Oncology Pharmacist AI

At Mayo Clinic Rochester MN (200 First Street SW, Rochester MN 55905; Olmsted County MN; FIGHT-202 ENROLLMENT: Mayo Clinic's Division of Medical Oncology — Gastrointestinal Oncology and Hepatology enrolled intrahepatic cholangiocarcinoma (iCCA) patients in FIGHT-202 (NCT02924376; Phase 2; pemigatinib 13.5 mg QD continuous [3 weeks on / 1 week off]; FGFR2 fusion/rearrangement cohort A primary endpoint ORR 35.5%; mDOR 7.5 months; mPFS 6.9 months; mOS 21.1 months; Cohort A 107 evaluable patients); HEPATOLOGY-ONCOLOGY INTERFACE: cholangiocarcinoma at Mayo Clinic involves combined hepatology-oncology pharmacy consultation (biliary drainage, ERCP, cholangioscopy + systemic therapy; pemigatinib occupational exposure occurs in pharmacy preparation and during patient contact); FGFR4-SPARING MONITORING CONTEXT: Mayo Clinic hepatology-oncology pharmacists track liver function tests (LFTs) for pemigatinib-treated patients differently than for pan-FGFR inhibitors — FGFR4 sparing predicts less bile acid perturbation; however, EHS Insight entry does not document FGFR4-sparing design rationale for occupational risk context; CONCURRENT FGFR INHIBITORS: Mayo Clinic simultaneously uses pemigatinib (FGFR2 fusions iCCA; FGFR4-sparing), futibatinib (FGFR2-altered iCCA; covalent pan-FGFR), and erdafitinib (urothelial; pan-FGFR1/2/3/4) — three FGFR inhibitors with distinct selectivity profiles and all EHS null returns for CAS lookup; EHS Insight: CAS 1628208-23-0 → "OSHA PEL: not established. ACGIH TLV: none. NIOSH REL: none — no OEL"; first FGFR4-sparing design absent; FGFR2 fusion cholangiocarcinoma biology absent; FGFR2 V565I gatekeeper resistance absent; selective vs pan-FGFR distinction absent; H340 H350 H361 absent; 46F hepatology-oncology pharmacist 14yr).

Integrating Glyphward into Pemigatinib AI EHS Monitoring

Glyphward integrates as a pre-scan gate at every pemigatinib CAS 1628208-23-0 monitoring data ingestion point — before Cority at Incyte Corporation Wilmington DE, before VelocityEHS at Almac Group Craigavon Northern Ireland, and before EHS Insight at Mayo Clinic Rochester MN. Threshold 22 reflects: OSHA/ACGIH/NIOSH regulatory null (NIOSH HD Category 1; no OSHA PEL; no ACGIH TLV; no NIOSH REL) + H340 H350 H361 absent [10 pts]; FIRST FGFR1/2/3-SELECTIVE INHIBITOR WITH FGFR4-SPARING DESIGN (FGFR4 IC50 ~30 nM; >25-fold FGFR1/2/3 selectivity; FGFR4 inhibition linked to bile acid synthesis via FGF19/FGFR4 axis) + FIRST KINASE INHIBITOR EVER FOR CHOLANGIOCARCINOMA / BILE DUCT CANCER (NDA 213736 April 17 2020; FGFR2 fusions ~10–15% iCCA; no prior kinase had cholangiocarcinoma indication) + FIGHT-202 ORR 35.5% (38/107 FGFR2 fusion/rearrangement cohort) + FGFR2 V565I gatekeeper resistance [5 pts]; Incyte Wilmington DE + Almac Craigavon NI + Mayo Clinic Rochester MN [3 pts]; FGFR4-sparing rationale and bile acid mechanism absent; cholangiocarcinoma FGFR2 fusion biology absent; selective vs pan-FGFR distinction absent; FGFR2 V565I gatekeeper resistance absent [4 pts]. Total: 10+5+3+4 = 22.

import asyncio
import httpx

async def scan_pemigatinib(cas: str, reading_ugm3: float) -> dict:
    """Scan pemigatinib with first-FGFR4-sparing and first-kinase-cholangiocarcinoma context."""
    async with httpx.AsyncClient(timeout=30) as client:
        resp = await client.post(
            "https://glyphward.com/api/v1/scan",
            json={
                "cas": cas,
                "reading_ugm3": reading_ugm3,
                "context": "first_fgfr1_2_3_selective_fgfr4_sparing_inhibitor_first_kinase_cholangiocarcinoma_bile_duct_nda_213736_april_2020_fight202_orr_35pct_fgfr2_v565i_gatekeeper"
            }
        )
    return resp.json()
    # Glyphward returns: hd_category, first_fgfr4_sparing_selective_inhibitor,
    #                    first_kinase_cholangiocarcinoma,
    #                    fgfr4_bile_acid_sparing_rationale,
    #                    fgfr2_v565i_gatekeeper_resistance,
    #                    h340_h350_h361_absent

if __name__ == "__main__":
    r = asyncio.run(scan_pemigatinib("1628208-23-0", 0.00036))
    print(r)
    # {'hd_category': 1, 'first_fgfr4_sparing_selective_inhibitor': True,
    #  'first_kinase_cholangiocarcinoma': True,
    #  'fgfr4_bile_acid_sparing_rationale': True,
    #  'fgfr2_v565i_gatekeeper_resistance': True,
    #  'h340_h350_h361_absent': True}